Verapamil is the medication with the strongest evidence for preventing both migraine and cluster headache
For a patient suffering from both migraine and cluster headache, verapamil should be the first-line preventive medication, as it has established efficacy for both conditions and is specifically recommended in current guidelines.
Rationale for Verapamil
Verapamil is the only medication with guideline-level support for both conditions:
For cluster headache prevention: The 2024 VA/DoD guidelines note that while evidence is insufficient to make a strong recommendation, verapamil remains the clinical standard at doses of at least 240 mg daily 1. The 2023 European Academy of Neurology guidelines provide a strong recommendation for verapamil at daily doses of at least 240 mg (maximum dose depends on efficacy and tolerability) 2.
For migraine prevention: While not among the top-tier recommendations in the most recent 2025 ACP guidelines 3, verapamil (as a calcium channel blocker) has established use in migraine prophylaxis and is commonly employed in clinical practice 4, 5.
Alternative Considerations
If verapamil is contraindicated or ineffective, consider these options:
CGRP Monoclonal Antibodies
Galcanezumab has evidence for both conditions but with important limitations:
Other CGRP antibodies (erenumab, fremanezumab) have strong evidence for migraine 1 but lack cluster headache data
Topiramate
- Weak recommendation for episodic and chronic migraine prevention 1
- Listed as an alternative treatment for cluster headache 2
- However, tolerability issues (cognitive side effects, paresthesias) may limit use
Lithium
- Recommended as an alternative for cluster headache 2
- Limited evidence for migraine prevention
- Requires therapeutic monitoring and has significant drug interactions
Important Clinical Caveats
Verapamil monitoring requirements:
- Baseline and follow-up ECGs are essential due to risk of PR interval prolongation and heart block
- Dose titration should be gradual
- Monitor blood pressure
Galcanezumab limitations:
- Do NOT use for chronic cluster headache (weak recommendation against) 1
- Expensive and may require prior authorization
- Only episodic cluster headache has supporting evidence
Avoid these medications:
- Gabapentin has a weak recommendation AGAINST for episodic migraine prevention 1
- Botulinum toxin is only for chronic migraine, not episodic migraine or cluster headache 1
Practical Implementation
Start with verapamil 120-240 mg daily, titrating upward based on response and tolerability (maximum doses vary but can reach 480-960 mg daily in divided doses for cluster headache). Obtain baseline ECG and repeat after dose increases. If verapamil fails or is contraindicated, consider galcanezumab for patients with episodic (not chronic) cluster headache and migraine, or topiramate if cost is a concern and cognitive side effects are acceptable.